BSc (Hons) (First Class, Brisbane, Australia, 1990), PhD (Aberdeen, 1997)
Manager, Centre for Genome Enabled Biology & Medicine
- About
-
- Email Address
- e.collie-duguid@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437958
- Office Address
School of Medicine, Medical Sciences and Nutrition. Room 4.015. Polwarth Bulding. Foresterhill. Aberdeen. AB25 2ZD
and
Centre for Genome Enabled Biology and Medicine. Room G17. 23 St Machar Drive. Old Aberdeen. Aberdeen. AB24 3RY.
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
Elaina Collie-Duguid was awarded a first class BSc (Hons) degree in molecular biology from the University of Queensland, Brisbane, Australia in 1990. Her time as a research assistant at the Centre for Molecular Biology and Biotechnology (currently The Institute of Molecular Bioscience), University of Queensland, was followed by a period of international travel, culminating in a move to Aberdeen in 1993 to begin a PhD in molecular and cellular biology at the Rowett Research Institute. In 1996, Dr Collie-Duguid took up post as a post-doctoral scientist in the Department of Medicine and Therapeutics at the University of Aberdeen and she now heads a Cancer Medicine research group with a particular focus on breast cancer within the Cancer Biomedicine programme.
Dr Collie-Duguid manages the Centre for Genome Enabled Biology and Medicine (CGEBM) at the University of Aberdeen. CGEBM provides strategic direction and coordinated management of the University of Aberdeen’s genomics facilities and facilitates genomics enabled interdisciplinary research by provision of specialised expertise, infrastructure, training, a focal point for collaboration and information exchange and genomics services to the research community. CGEBM provides specialist services in next generation sequencing (NGS), microarrays, bioinformatics and biostatistics. CGEBM helps to drive genome focused research forward by developing and exploiting modern genomic technologies to accelerate discovery of novel approaches to improve human health, the environment and agriculture within the diverse programmes of applied translational, clinical, biomedical and biological research at the University of Aberdeen.
External Memberships
Scientific Member of the Experimental and Translational Medicine Research Committee of the Chief Scientist Office, 2009-2014
Scientific Member of the Biomedical and Therapeutics Research Committee of the Chief Scientist Office, 2005-2009.
- Research
-
Research Overview
Dr Collie-Duguid's research interest is to understand the molecular and cellular mechanisms controlling tumorigenesis, survival of cancer patients and chemoresistance in solid tumours, with a particular focus on breast cancers. Biomarker discovery for prediction of clinical outcomes, including response to therapy; and novel drug target identification for drug development are key elements of her translational research programme. Dr Collie-Duguid has an interest in using genomic tools to understand human disease and important biological processes.
- Teaching
-
Teaching Responsibilities
Dr Collie-Duguid teaches on level 5 courses MB5021 Bioinformatics, MT5003 Drug Metabolism and Toxicology, and MT5515 Research Methods, level 4 PA4302 Molecular Toxicology, level 3 PA3802 Mechanisms of Disease and Principles of Chemotherapy and Intercalated BSc MB ChB teaching in Genetic variation and Bioinformatics, and provides research project supervision to level 5 MSc students in the field of genomics.
- Publications
-
Page 3 of 3 Results 51 to 64 of 64
Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines
FEBS Letters, vol. 531, no. 3, pp. 415-420Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/S0014-5793(02)03575-5
Pyrimidine Metabolism and G1/S transition in colon tumours.
British Journal of Cancer, vol. 86, no. S1Contributions to Journals: ArticlesThymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal cancer
International Journal of Cancer, vol. 94, no. 2, pp. 297-301Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1002/ijc.1462
A clinician's guide to the polmerase chain reaction
UroOncology, vol. 1, pp. 103-112Contributions to Journals: Literature ReviewsCloning and initial characterization of the human DPYD gene promoter
Biochemical and Biophysical Research Communications, vol. 271, pp. 28-35Contributions to Journals: ArticlesEstimation of dihydropyrimidine dehydrogenase activity: Does it have a role in cancer therapy?
Annals of Oncology, vol. 11, pp. 255-257Contributions to Journals: EditorialsKnown variant DPYD alleles do not explain DPD deficiency in cancer patients
Pharmacogenetics, vol. 10, pp. 217-223Contributions to Journals: ArticlesTherapeutic opportunities from tumour biology in metastatic colon cancer
European Journal of Cancer, vol. 36, pp. 1706-1712Contributions to Journals: ArticlesEthnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations
Genomics, vol. 58, no. 3, pp. 310-312Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1006/geno.1999.5833
Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals
Pharmacogenetics, vol. 9, pp. 773-776Contributions to Journals: ArticlesThe frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations
Pharmacogenetics, vol. 9, pp. 37-42Contributions to Journals: ArticlesThiopurine methyltransferase alleles in British and Ghanaian populations
Human Molecular Genetics, vol. 8, pp. 367-370Contributions to Journals: ArticlesThiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine
Annals of Internal Medicine, vol. 129, no. 9, pp. 716-718Contributions to Journals: ArticlesNomenclature for human DPYD alleles
Pharmacogenetics, vol. 8, pp. 455-459Contributions to Journals: Articles